Compare Stocks → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NYSEARCA:BULNYSEAMERICAN:GDPNASDAQ:PHAR Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBULPacer US Cash Cows Growth ETF$41.18+1.8%$40.86$32.36▼$42.72$47.35M0.896,557 shs661 shsGDPGoodrich Petroleum$23.02$0.00$8.61▼$26.66$331.24M1.697,879 shsN/APHARPharming Group$9.61-8.0%$10.83$9.27▼$16.71$644.93M0.162,610 shs1,703 shs7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBULPacer US Cash Cows Growth ETF-0.42%+1.41%-3.67%+10.24%+17.65%GDPGoodrich Petroleum0.00%0.00%0.00%0.00%0.00%PHARPharming Group-2.93%-0.16%-11.36%-22.01%-11.81%The Next Step of Their Control Is Here … (Ad)Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.4 simple steps to protect your privacy and money before it’s too late.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBULPacer US Cash Cows Growth ETFN/AN/AN/AN/AN/AN/AN/AN/AGDPGoodrich PetroleumN/AN/AN/AN/AN/AN/AN/AN/APHARPharming Group2.5709 of 5 stars3.55.00.00.02.60.00.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBULPacer US Cash Cows Growth ETF0.00N/A$43.676.06% UpsideGDPGoodrich PetroleumN/AN/AN/AN/APHARPharming Group3.00Buy$37.00285.02% UpsideCurrent Analyst RatingsLatest BUL, GDP, EEG, PHAR, and FOG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/14/2024PHARPharming GroupHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$37.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBULPacer US Cash Cows Growth ETFN/AN/AN/AN/AN/AN/AGDPGoodrich Petroleum$93.83M3.53$4.13 per share5.57$3.28 per share7.02PHARPharming Group$245.32M2.63$0.10 per share100.85$3.26 per share2.95Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBULPacer US Cash Cows Growth ETFN/AN/A9.14∞N/AN/AN/AN/AN/AGDPGoodrich Petroleum-$44.14M-$4.70N/A2.31N/A-39.91%131.44%16.12%N/APHARPharming Group-$10.55M-$0.14N/AN/AN/A-4.13%-4.53%-2.14%5/8/2024 (Confirmed)Latest BUL, GDP, EEG, PHAR, and FOG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2024N/APHARPharming Group$0.0050N/A-$0.0050N/AN/AN/A3/14/2024Q4 2023PHARPharming Group$0.05-$0.03-$0.08-$0.02$71.83 million$81.20 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBULPacer US Cash Cows Growth ETF$0.240.58%N/AN/AN/AGDPGoodrich PetroleumN/AN/AN/AN/AN/APHARPharming GroupN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBULPacer US Cash Cows Growth ETFN/AN/AN/AGDPGoodrich Petroleum3.300.240.24PHARPharming Group0.624.063.33OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBULPacer US Cash Cows Growth ETFN/AGDPGoodrich Petroleum67.26%PHARPharming Group0.03%Insider OwnershipCompanyInsider OwnershipBULPacer US Cash Cows Growth ETFN/AGDPGoodrich Petroleum13.60%PHARPharming Group2.07%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBULPacer US Cash Cows Growth ETFN/A1.15 millionN/ANot OptionableGDPGoodrich Petroleum2,02014.39 million12.43 millionNot OptionablePHARPharming Group33267.11 million65.72 millionNot OptionableBUL, GDP, EEG, PHAR, and FOG HeadlinesSourceHeadlinePharming Group (NASDAQ:PHAR) Trading Down 8.8%marketbeat.com - April 26 at 5:57 PMPharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awardsfinance.yahoo.com - April 24 at 2:17 AMPharming Group to report first quarter 2024 financial results on May 8finance.yahoo.com - April 24 at 2:17 AMPharming Group (NASDAQ:PHAR) Shares Gap Down to $10.00marketbeat.com - April 22 at 1:31 PMPharming Group (PHAR) Surges 7.2%: Is This an Indication of Further Gains?zacks.com - April 22 at 6:31 AMPharming Group (NASDAQ:PHAR) Sees Large Volume Increaseamericanbankingnews.com - April 21 at 4:44 AMPharming Group (NASDAQ:PHAR) Hits New 1-Year Low at $9.35americanbankingnews.com - April 20 at 4:40 AMPharming Group N.V.: Pharming Group announces the repurchase of outstanding €125 million convertible bonds due 2025finanznachrichten.de - April 19 at 4:05 PMPharming Group (NASDAQ:PHAR) Sees Strong Trading Volumemarketbeat.com - April 19 at 1:37 PMPharming Group N.V.: Pharming Group announces the placement of €100 million convertible bonds due 2029finanznachrichten.de - April 18 at 6:18 PMPharming Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025finance.yahoo.com - April 18 at 8:17 AMPharming Group (NASDAQ:PHAR) Stock Price Down 6.8%marketbeat.com - April 15 at 1:55 PMPharming Group (NASDAQ:PHAR) Shares Down 5% marketbeat.com - April 9 at 3:19 PMEnrollment completed for trial of drug to treat children with rare primary immunodeficiencyoutsourcing-pharma.com - April 8 at 8:50 AMPharming announces completion of enrollment in pediatric clinical trial of leniolisibfinance.yahoo.com - April 8 at 1:34 AMPharming Group (NASDAQ:PHAR) Shares Gap Down to $10.96marketbeat.com - April 4 at 6:21 PMPharming Group announces the filing of its 2023 Annual Report and Form 20-Ffinance.yahoo.com - April 4 at 1:14 AMUber to pay $178 million in Australia taxi class action settlementmsn.com - March 18 at 3:45 AMPharming reports Q4 resultsmsn.com - March 15 at 7:46 PMPharming Group N.V. 2023 Q4 - Results - Earnings Call Presentationseekingalpha.com - March 14 at 9:06 AMPharming Group N.V.: Pharming Group to report fourth quarter and full year 2023 financial results on March 14finanznachrichten.de - February 29 at 6:26 AMPharming Group N.V. (PHGN.F)finance.yahoo.com - February 20 at 3:10 PMPharming Group N.V.: Pharming Group to participate in February investor conferencesfinanznachrichten.de - February 8 at 3:55 AMPharming Group to participate in February investor conferencesfinance.yahoo.com - February 8 at 3:55 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines5 Stocks in the Current Bull Market with Upside to ComeApril 5, 2024 10:14 AMView 5 Stocks in the Current Bull Market with Upside to ComeGE Aerospace is Ready for Liftoff After Strong EarningsApril 24, 2024 9:07 AMView GE Aerospace is Ready for Liftoff After Strong EarningsBargain Alert: AMD is on the Verge of a Massive Catchup PlayApril 4, 2024 8:56 AMView Bargain Alert: AMD is on the Verge of a Massive Catchup PlayAnalysts are Bullish on These 4 Oversold Large Cap StocksApril 1, 2024 11:37 AMView Analysts are Bullish on These 4 Oversold Large Cap StocksWhat's Driving Tesla Lower Ahead of its Earnings?April 18, 2024 8:45 AMView What's Driving Tesla Lower Ahead of its Earnings?All Headlines Company DescriptionsPacer US Cash Cows Growth ETFNYSEARCA:BULThe Pacer US Cash Cows Growth ETF (BUL) is an exchange-traded fund that is based on the Pacer US Cash Cows Growth index. The fund tracks a market cap-weighted index of large- and mid-cap US growth equities selected using fundamental factors. BUL was launched on May 2, 2019 and is managed by Pacer.Goodrich PetroleumNYSEAMERICAN:GDPGoodrich Petroleum Corp. engages in the exploration, development, and production of oil and natural gas on properties. It holds interests in the Haynesville Shale Trend in northwest Louisiana and East Texas; Tuscaloosa Marine Shale Trend located in southwest Mississippi and southeast Louisiana; and the Eagle Ford Shale Trend situated in South Texas. The company was founded in 1995 and is headquartered in Houston, TX.Pharming GroupNASDAQ:PHARPharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's commercialized product is RUCONEST, a plasma-free rhC1INH protein replacement therapy for the treatment acute hereditary angioedema (HAE) attacks. It also engages in the development of leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome; OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE; and alpha-glucosidase therapy for the treatment of Pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. is headquartered in Leiden, the Netherlands. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
